SCIENION AG, a leading provider of ultra-low volume precision liquid handling systems, and Greiner Bio-One, a leading manufacturer of synthetic materials for health services and a pioneer of new medical technology, today announced that they have entered into an agreement to co-develop advanced tests and integrated solutions for rapid and multiplexed diagnostics.
Berlin, Germany, and Kremsmünster, Austria, November 13, 2015: The emerging field of rapid diagnostic tests is becoming increasingly important in a variety of applications. For infectious diseases, the time to diagnosis is a critical factor for ensuring successful management. This collaboration will focus on the development of new tests that will optimize patient care by providing sensitive and accurate test results within only 75 minutes. The collaboration will bring together SCIENION's core competencies in ultra-low volume liquid dispensing, assay miniaturization, and microarray manufacturing with Greiner Bio-One’s innovative Genspeed® testing system.
Dr. Holger Eickhoff, CEO of SCIENION AG, states: "We believe combining our expertise and sciFLEXARRAYER technology with Greiner Bio-One’s Genspeed® platform may enable us to bring personalized healthcare to the next level. We look forward to collaborating with Greiner Bio-One on this exciting development to optimize treatment outcomes for patients."
"We are looking forward to this collaboration to address the significant market need in the detection of human pathogens utilizing our Genspeed® platform", said Dr. Max Sonnleitner, Head of Rapid Testing Technologies/ Business Development at Greiner Bio-One Diagnostics. "Similar to our Genspeed® MRSA testing system, all jointly developed future tests have the potential to become very successful on the market".
Visit us at MEDICA 2015, November 16 - 19, 2015 in Düsseldorf, Germany. Please visit us at booth A42 in hall 3.
About Greiner Bio-One International GmbH
Greiner Bio-One specializes in the development, production and distribution of quality plastic products for laboratory use. The company is a technology partner for hospitals, laboratories, universities, research institutes, the diagnostic and pharmaceutical industry, and the biotechnology industry. Greiner Bio-One is split into four divisions: Preanalytics, BioScience, Diagnostics and OEM. Greiner Bio-One International GmbH generated sales of EUR 388 million in 2014 and has 1800 employees, 23 subsidiaries and numerous distribution partners in more than 100 countries. Greiner Bio-One is part of Greiner Holding, which is based in Kremsmünster (Austria).
Greiner Bio-One GmbH – Diagnostics Division
The division has four strategic focuses in the field of diagnostics: Screening test procedures for sexually transmitted diseases, hospital acquired infections, vaccine safety, and customer-specific products. Two completely different detection systems satisfy mass analysis (screening) requirements, as well as individual analysis requirements for acute medicine.
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded over one decade. SCIENION provides flexible solutions for research and development, wherein solutions for production purposes are customized. Systems and software are characterized by their versatility, precision and robustness. The company is a renowned specialist for ultra-low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in New Jersey, USA.